SCCM Resource Library-Urine Good Hands: Updates in Critical Care Nephrology

Urine Good Hands: Updates in Critical Care Nephrology

Video Transcription

Video Summary

Julie Farah, from the University of Tennessee College of Pharmacy, discusses updates in critical care nephrology, specifically the nephrotoxic potential of the drug combination piperacillin-tazobactam and vancomycin. Historical data suggest increased risk of acute kidney injury (AKI) with this combination, but newer studies, including the ACORN randomized trial, question this assessment. Studies reveal creatinine rise may not correlate to real kidney damage, suggesting pseudotoxicity. Findings demonstrate short durations of these drugs might not significantly increase AKI risk. Novel biomarkers such as cystatin C offer more reliable insights into kidney function.

Asset Caption

Year in Review | Year in Review: Clinical Pharmacy and Pharmacology (Flipped Classroom)

Meta Tag

Content Type Presentation

Membership Level Professional

Membership Level Select

Year 2024

Keywords

critical care nephrology

piperacillin-tazobactam

vancomycin

acute kidney injury

cystatin C

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.